Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment
Autore:
Thiebaut, R; Morlat, P; Jacqmin-Gadda, H; Neau, D; Mercie, P; Dabis, F; Chene, G;
Indirizzi:
Univ Bordeaux 2, INSERM, ISPED, Unite 330, F-33076 Bordeaux, France Univ Bordeaux 2 Bordeaux France F-33076 te 330, F-33076 Bordeaux, France CHU Bordeaux, Ctr Informat & Soins Immunodeficience Humaine, Bordeaux, France CHU Bordeaux Bordeaux France Immunodeficience Humaine, Bordeaux, France
Titolo Testata:
AIDS
fascicolo: 8, volume: 14, anno: 2000,
pagine: 971 - 978
SICI:
0269-9370(20000526)14:8<971:CPOHIA>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
CUBIC MILLIMETER; CONTROLLED TRIAL; RNA; THERAPY; PLASMA; AIDS; VIRUS; RISK; ASSOCIATION; INHIBITORS;
Keywords:
HIV infection; disease progression; viral response; cohort study; antiretroviral combination;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Dabis, F Univ Bordeaux 2, INSERM, ISPED, Unite 330, 146 Rue Leo Saignat, F-33076 Bordeaux, France Univ Bordeaux 2 146 Rue Leo Saignat Bordeaux France F-33076 ance
Citazione:
R. Thiebaut et al., "Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment", AIDS, 14(8), 2000, pp. 971-978

Abstract

Objective: To compare HIV-disease progression according to changes of plasma HIV RNA observed in the year following initiation of a new antiretroviral treatment. Design: Prospective cohort treated with two nucleoside analogues or a triple combination including a protease inhibitor. Methods: A Cox model was used to estimate the effect of viral response during the first year after initiation of treatment on the subsequent occurrence of new AIDS-defining events or death. Viral response was fitted either as HIV RNA reduction during the initial 4-12 months of treatment or reduction during the first month. Results: Among 773 patients (47% with triple drug combination) followed for a median period of 27 months, 62 patients experienced a clinical event. Poor viral responders (at least two measurements > 3.7 log(10) copies/ml during 4-12 months of treatment) had a higher risk of disease progression thangood responders (RNA < 2.7 log(10) copies/ml) after adjustment [hazard ratio (HR), 2.24; 95% confidence interval (Cl), 1.17-4.29]. Intermediate responders (2.7 less than or equal to RNA less than or equal to 3.7 log(10) copies/ml) had a risk of progression comparable with that of good responders (HR, 1.43; 95% Cl, 0.64-3.22). A large initial viral reduction was also a protective factor for clinical progression (HR, 0.51 for 1 log(10) copies/ml increase of the reduction; 95% Cl, 0.31-0.85) and was associated with the viral response during the subsequent 4-12 month period. No patient with a reduction < 0.5 log(10) copies/ml in the first month was classified as a good responder in the subsequent 4-12 month period (P < 0.01). Conclusions: A sustained HIV RNA > 3.7 log(10) copies/ml should suggest a prompt change of treatment. When the reduction in HIV RNA is < 0.5 log(10) after 1 month of treatment, this action should be anticipated. A sustained HIV RNA level between 2.7 and 3.7 log(10) copies/ml may permit the deferralof a change of drug regimen according to the patient's history and therapeutic options. (C) 2000 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 07:38:05